- Conditions
- Hidradenitis Suppurativa
- Interventions
- Lutikizumab, Placebo
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 21,461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma, Autonomic Imbalance, Cancer Survivorship
- Interventions
- Ivabradine, Placebo Oral Tablet
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
- Conditions
- Breast Reconstruction
- Interventions
- DuraSorb®
- Device
- Lead sponsor
- Surgical Innovation Associates, Inc.
- Industry
- Eligibility
- 22 Years to 70 Years · Female only
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Pre-diabetes, Overweight, Metabolic Syndrome
- Interventions
- Diabetes Genetic Counseling, No genetic counseling
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 48
- States / cities
- Irvine, California • Loma Linda, California • Palm Springs, California + 39 more
- Conditions
- Inflammatory Bowel Disease, Depression
- Interventions
- Cognitive Behavioral Therapy, Supportive Non-directive Therapy (SNDT)
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Pittsburgh, Pennsylvania
- Conditions
- Healthy
- Interventions
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Air Pollution, Cardiovascular Health
- Interventions
- HEPA air filtration
- Other
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
- Interventions
- Deramiocel (CAP-1002), Placebo
- Biological
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
- Conditions
- Aging
- Interventions
- Cognitive training program
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ventricular Tachycardia
- Interventions
- Intramural Needle Ablation Catheter
- Device
- Lead sponsor
- William Stevenson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
- Conditions
- COVID-19
- Interventions
- Danicopan, Placebo, Remdesivir
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more
- Conditions
- Metastatic Cancer, Prostate Cancer
- Interventions
- Docetaxel, Imatinib mesylate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Gastrointestinal Disorders, Autism Spectrum Disorders
- Interventions
- evaluation visit by a pediatric gastroenterologist
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vascular Diseases
- Interventions
- Placebo, BMS-582949, Atorvastatin, Statin
- Other · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 17
- States / cities
- Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more
- Conditions
- COVID-19
- Interventions
- RDV, Placebo to Match RDV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 92
- States / cities
- Chandler, Arizona • Tucson, Arizona • Eureka, California + 78 more
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Memantine, Placebo, Whole brain radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 229
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 183 more
- Conditions
- Multiple Myeloma
- Interventions
- bb2121, Lenalomide, Talquetamab
- Biological · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more
- Conditions
- Opioid Use Disorder
- Interventions
- Recovery Community Center Participation, Enhance Treatment as Usual
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Survivorship, Treatment Compliance, Treatment Adherence, Treatment Refusal
- Interventions
- Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 11
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Concord, Massachusetts + 7 more
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
- Interventions
- Sapphire 3 Coronary Dilatation Catheter
- Device
- Lead sponsor
- OrbusNeich
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 12
- States / cities
- Stanford, California • Torrance, California • Atlanta, Georgia + 5 more